Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
---|
06/15/2011 | EP2333062A1 RNA-interference by single-stranded RNA molecules |
06/15/2011 | EP2333049A1 Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
06/15/2011 | EP2332989A1 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
06/15/2011 | EP2332983A2 Identification of tumor-associated cell-surface antigens for diagnosis and theapy |
06/15/2011 | EP2332981A2 Identification of tumor-associated cell-surface antigens for diagnosis and theapy |
06/15/2011 | EP2332980A2 Identification of tumor-associated cell-surface antigens for diagnosis and theapy |
06/15/2011 | EP2332979A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
06/15/2011 | EP2332978A1 Novel polypeptides involved in immune response |
06/15/2011 | EP2332976A1 Novel polypeptides involved in immune response |
06/15/2011 | EP2332974A2 Osteoprotegerin |
06/15/2011 | EP2332973A2 Differential in tumour gene products and use of same |
06/15/2011 | EP2332972A1 Novel Beta-Actin and RPS21 promoters and uses thereof |
06/15/2011 | EP2332582A1 ACE2 activation for treatment of heart, lung and kidney disease and hypertension |
06/15/2011 | EP2332574A1 HCV NS3/4A Sequences |
06/15/2011 | EP2332573A1 Chimeric alphavirus replicon particles |
06/15/2011 | EP2332572A1 Nucleic acid vaccines for prevention of Flavivirus |
06/15/2011 | EP2331708A1 Tbc1d7 as tumor marker and therapeutic target for cancer |
06/15/2011 | EP2331692A1 Modified thromboxane a2 receptor promoter sequence |
06/15/2011 | EP2331684A1 Production of n-acylated sulphur-containing amino acids with microorganisms having enhanced n-acyltransferase enzymatic activity |
06/15/2011 | EP2331566A1 Method and compositions for enhanced anti-tumor effector functioning of t cells |
06/15/2011 | EP2331143A2 Treatment of scleroderma |
06/15/2011 | EP2331142A2 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells |
06/15/2011 | EP2331141A2 Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
06/15/2011 | EP2331115A2 Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs |
06/15/2011 | EP1871890B1 Methods and devices for delivering a therapeutic product to the ocular sphere of a subject |
06/15/2011 | EP1842921B1 Recombined adenovirus p53 preparation for treating tumor |
06/15/2011 | EP1706140B1 Methods for tailoring the immune response to an antigen or immunogen |
06/15/2011 | EP1642981B1 RECOMBINANT GENE MEDICINE OF ADENOVIRUS VECTOR AND GENE p53 FOR TREATING PROLIFERATIVE DISEASES |
06/15/2011 | EP1616000B1 Expression of proteins in cord blood-derived endothelial cells |
06/15/2011 | EP1417229B1 Methods and compounds for the targeting of protein to exosomes |
06/15/2011 | EP1404710B1 Identification of ses-3 (spr-5) in c. elegans and the uses of the same |
06/15/2011 | EP0939804B2 NEUTROKINE alpha |
06/15/2011 | CN1974591B SiRNA expression template for treating liver necrosis and liver fibrosis |
06/15/2011 | CN1837362B SiRNA for inhibiting expression of SARS coronavirus N protein and encoding gene thereof |
06/15/2011 | CN1780912B Method for inhibiting cell growth and composition therefor |
06/15/2011 | CN1680432B Viral protein |
06/15/2011 | CN102099471A Aptamer against il-17 and use thereof |
06/15/2011 | CN102099467A SiRNA of human osteopontin |
06/15/2011 | CN102094042A Recombinant vector of ZNF300 gene and application thereof |
06/15/2011 | CN102094020A RNA (Ribose Nucleic Acid) interference sequence and recombined interference plasmid for inhibiting fucosyltransferase I synthesized by LeY carbohydrate antigens |
06/15/2011 | CN102094019A RNA (Ribose Nucleic Acid) interference sequence and recombined interference plasmid for inhibiting fucosyltransferase IV synthesized by LeY carbohydrate antigens |
06/15/2011 | CN102093477A Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
06/15/2011 | CN102091334A Method for preparing adenovirus-chitosan nano composite material |
06/15/2011 | CN102091333A Application of miR-124 in preparation of medicines for preventing infectious shock |
06/15/2011 | CN102091027A Method for preparing antitumor small interfering RNA carrying magnetic nano probe |
06/15/2011 | CN101608182B Oncogene, recombinant protein derived therefrom, and uses thereof |
06/15/2011 | CN101591658B ING4 and IL-24 dual gene co-expression vector and application thereof |
06/15/2011 | CN101219221B Adenovirus carrier vaccine carrying HIV gene |
06/15/2011 | CN101195657B Type I cell factor receptor sample molecule, encoding gene and application thereof |
06/15/2011 | CN101130770B Nucleotide molecule SR2B and application of the same in producing antidiabetic medicament |
06/15/2011 | CN101130769B Nucleotide molecule SR4B and application of the same in producing antidiabetic medicament |
06/14/2011 | US7960527 Nucleic acid and corresponding protein entitled 151P3D4 useful in treatment and detection of cancer |
06/14/2011 | US7960525 Gene repair involving in vivo excision of targeting DNA |
06/14/2011 | US7960507 Tumor associated antigen peptides and use of same as anti-tumor vaccines |
06/14/2011 | US7960363 Therapeutic agent for wounds and screening method for the same |
06/14/2011 | US7960361 Formulating an anti-cancer vaccine comprising an agent that can stimulate an immune response against IL-13R alpha 2 outside of the subject, and administering the vaccine to the subject |
06/14/2011 | US7960357 PKR activation via hybridization chain reaction |
06/14/2011 | US7960356 Induces production of a cytokine or activates dendritic cells, natural killer cells and monocytes; autoimmune disorders; vaccine |
06/14/2011 | US7960102 Regulated aptamer therapeutics |
06/14/2011 | US7959918 Methods for treating vascular disease |
06/14/2011 | US7959659 Bioabsorbable stents; vascular disorders, occlusion treatment such as restenosis or vulnerable plaque; atherosclerosis, diabetes; anticoagulants |
06/14/2011 | CA2526670C Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith |
06/14/2011 | CA2446260C Novel expression vectors and uses thereof |
06/14/2011 | CA2426292C Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression |
06/14/2011 | CA2413546C Modification of hepatitis b core antigen |
06/14/2011 | CA2399846C Gm-negative ehv-mutants |
06/14/2011 | CA2365416C Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
06/14/2011 | CA2327389C Dna vaccine for horses containing as at least one adjuvant, polymers of acrylic or methacrylic acid, or copolymers of maleic anhydride and ethylene |
06/14/2011 | CA2301327C Use of herpes vectors for tumor therapy |
06/14/2011 | CA2182621C Galanin receptor, nucleic acids, transformed cells and uses thereof |
06/09/2011 | WO2011068916A1 Pegylated polyplexes for polynucleotide delivery |
06/09/2011 | WO2011068546A2 Prognosis, diagnosis and identification of multiple myeloma based on global gene expression profiling |
06/09/2011 | WO2011068019A1 Retrograde transport viral vector system having envelope comprising fused glycoprotein |
06/09/2011 | WO2011066681A1 Human high metastatic nasopharyngeal carcinoma cell strain s18 stably expressing tet-off advanced, construction method and uses thereof |
06/09/2011 | WO2011066615A1 Methods and compositions for increasing titer of recombinant porcine adenovirus-3 vectors |
06/09/2011 | WO2011047318A8 Supercoiled minicircle dna for gene therapy applications |
06/09/2011 | WO2010088565A8 Nucleic acid delivery using modified chitosans |
06/09/2011 | WO2010060186A8 Antibodies that specifically block the biological activity of a tumor antigen |
06/09/2011 | US20110136743 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
06/09/2011 | US20110136221 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities |
06/09/2011 | US20110135718 Viral particle-like structure in physiological conditions, and method of forming it |
06/09/2011 | US20110135710 Methods and Compositions for the Inhibition of Gene Expression |
06/09/2011 | US20110135682 Recombinant Bicistronic Flaviviruses and Methods of Use Thereof |
06/09/2011 | US20110135677 Circovirus sequences associated with piglet weight loss disease (PWD) |
06/09/2011 | US20110135652 Novel Use of Idbf |
06/09/2011 | US20110135614 Modified growth hormone |
06/09/2011 | US20110135597 Uses of Mammalian Cytokine; Related Reagents |
06/09/2011 | US20110135595 Neuregulin based methods and compositions for treating cardiovascular disease |
06/09/2011 | CA2782676A1 Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
06/08/2011 | EP2330219A2 Method for drug discovery, disease treatment and diagnosis using metabolomics |
06/08/2011 | EP2330213A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
06/08/2011 | EP2330194A2 Non-sequence complementary antiviral oligonucleotides |
06/08/2011 | EP2330192A1 Polypeptides and polynucleotides from coagulase-negative staphylococci |
06/08/2011 | EP2330188A1 Circovirus sequences associated with porcine wasting disease (PWD) |
06/08/2011 | EP2330129A2 Anti-TNF antibodies, compositions, methods and uses |
06/08/2011 | EP2330123A2 HIV resistance genes |
06/08/2011 | EP2330111A2 Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
06/08/2011 | EP2329854A2 Implant coating with nucleic acids |
06/08/2011 | EP2329830A2 Antisense inhibition of PTP1B expression |
06/08/2011 | EP2329827A2 Methods and immune modulatory nucleic acid compositions for preventing and treating disease |